Edition:
India

Trovagene Inc (TROV.OQ)

TROV.OQ on NASDAQ Stock Exchange Capital Market

0.79USD
20 Jul 2018
Change (% chg)

$0.04 (+4.67%)
Prev Close
$0.75
Open
$0.76
Day's High
$0.81
Day's Low
$0.74
Volume
373,139
Avg. Vol
86,865
52-wk High
$13.32
52-wk Low
$0.72

Select another date:

Thu, May 10 2018

BRIEF-Trovagene Files For Offering Of Up To $15 Mln Of Class A Units Of Common Stock And Up To $15 Mln Of Class B Units Of Common Stock

* TROVAGENE INC FILES FOR OFFERING OF UP TO $15.0 MILLION OF CLASS A UNITS OF COMMON STOCK AND UP TO $15.0 MILLION OF CLASS B UNITS OF COMMON STOCK - SEC FILING Source text: [https://bit.ly/2rAnkbg] Further company coverage:

BRIEF-Trovagene Reports Q1 Loss Per Share $0.09

* TROVAGENE ANNOUNCES FIRST QUARTER 2018 HIGHLIGHTS AND FINANCIAL RESULTS

BRIEF-Trovagene Reports Q4 Loss Per Share $0.06

* TROVAGENE ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

BRIEF-Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Phase 1B/2 Clinical Trial Of PCM-075

* TROVAGENE ANNOUNCES COMPLETION OF CYCLE-ONE DOSING IN FIRST PATIENT ENROLLED IN ITS PHASE 1B/2 CLINICAL TRIAL OF PCM-075 IN ACUTE MYELOID LEUKEMIA (AML) Source text for Eikon: Further company coverage:

BRIEF-Trovagene Initiates Unite Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer

* TROVAGENE ANNOUNCES INITIATION OF UNITE PHASE 2 CLINICAL TRIAL OF PCM-075 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) Source text for Eikon: Further company coverage:

Select another date: